| --- | --- | --- | |-------|-------|-------| | | | | | | | | | | | | FO RWARD LO O KI NG STATEM ENTS & NO N-G AAP FI NANCI AL M EASURES Forward-LookingStatements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation, statements regarding our forecasted financial ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37856 Medpace Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 32-0434904 (State or other jurisdicti ...

Medpace Holdings, Inc. (NASDAQ:MEDP) Q4 2020 Earnings Conference Call February 16, 2021 9:00 AM ET Company Participants Kevin Brady - Executive Director of Finance Jesse Geiger - CFO & COO, Laboratory Operations August Troendle - Chairman, President & CEO Conference Call Participants David Windley - Jefferies Donald Hooker - KeyBanc Capital Markets Erin Wright - Cr??dit Suisse Alexander Draper - Truist Securities Operator Good day, ladies and gentlemen, and welcome to the Medpace Fourth Quarter and Full Yea ...

| --- | --- | --- | --- | |-------|-------------------|---------------------------|-------| | | | | | | | | | | | | FINANCIAL RESULTS | Q3 2020 OCTOBER 26, 2020 | | FORWARD LOOKING STATEMENTS & NON-GAAP FINANCIAL MEASURES Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking s ...

For the quarterly period ended September 30, 2020 or UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37856 Medpace Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 32-0434904 (State or other j ...

Medpace Holdings, Inc. (NASDAQ:MEDP) Q3 2020 Earnings Conference Call October 27, 2020 9:00 AM ET Company Participants Kevin Brady ??? Executive Director of Finance August Troendle ??? President and Chief Executive Officer Jesse Geiger ??? Chief Financial Officer and Chief Operating Officer of Laboratory Operations Conference Call Participants John Kreger ??? William Blair Sandy Draper ??? Truist Dave Windley ??? Jefferies Operator Good day, ladies and gentlemen, and welcome to the Medpace Third Quarter Ear ...

Company Overview - Medpace is a scientifically-driven, full-service CRO focused on delivering timely and efficient results for customers [6] - The company has a high-science approach with deep therapeutic expertise in areas like oncology, metabolic diseases, and cardiovascular diseases [6, 9] - Medpace operates globally with approximately 3,400 employees in 37 countries [7] Financial Performance - In 2019, Medpace's revenue was $861 million [9] - The company's backlog has shown consistent growth, reaching $1,294.2 million in Q1 2020 [23] - Medpace has demonstrated a strong net book-to-bill ratio, with 1.22x in Q1 2020 [20] - The company's EBITDA margin was 17.6% in Q1 2020 [25] - Medpace generated $43.6 million in Free Cash Flow in Q1 2020 [26] Market and Customer Focus - Medpace focuses on small and mid-sized biopharmaceutical companies, which represent an attractive R&D growth segment [7, 11, 16] - The company estimates its core addressable market to be $45 billion [13] - Small- and Mid-sized Biopharmaceutical CRO Addressable Market is $16 billion [14] - The top ten customers represented 29% of 2019 revenue, indicating a diversified customer base [7, 11]

Q2 2020 Key Operating Highlights - Net revenue for Q2 2020 was $205 million, a decrease of 43% compared to $2141 million in Q2 2019[7] - Net new business awards decreased by 90% from $2792 million in Q2 2019 to $2541 million in Q2 2020[7] - Ending backlog increased by 146% to $13428 million in Q2 2020, compared to $11717 million in Q2 2019[7] - Backlog conversion rate was 158% for Q2 2020, compared to 193% in Q2 2019[7] - Headcount increased by 56% to 3372 in Q2 2020, compared to 3193 in Q2 2019[7] Q2 2020 Key Financial Highlights - EBITDA for Q2 2020 was $35 million, a decrease of 129% compared to $402 million in Q2 2019, with a margin of 171%[10] - Net income for Q2 2020 was $241 million, a decrease of 122% compared to $275 million in Q2 2019, resulting in diluted earnings per share of $064[10] - Year-to-date revenue increased by 51% to $4359 million in 2020 from $4148 million in 2019[10] - Year-to-date net income increased by 137% to $531 million in 2020 from $467 million in 2019, with diluted earnings per share of $140[10] Full Year 2020 Guidance - The company projects net revenue between $880 million and $920 million, representing a growth rate of 22% to 69%[19] - The company anticipates EBITDA between $180 million and $190 million, representing a growth rate of 203% to 270%[19] - The company forecasts GAAP net income between $136 million and $144 million, representing a growth rate of 354% to 434%, with GAAP net income per diluted share between $362 and $383[19] Cash Flow - Free cash flow for Q2 2020 was $349 million, with a free cash flow conversion rate of 998%[16] - Net cash position increased to $1609 million[16]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37856 Medpace Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 32-0434904 (State or other jurisd ...

Medpace Holdings, Inc. (NASDAQ:MEDP) Q2 2020 Earnings Conference Call July 28, 2020 9:00 AM ET Company Participants Kevin Brady - Executive Director, Finance August Troendle - Chairman, President & CEO Jesse Geiger - CFO & COO, Laboratory Operations Conference Call Participants David Windley - Jefferies John Kreger - William Blair & Company Alexander Draper - SunTrust Robinson Humphrey Operator Good day, ladies and gentlemen, and welcome to the Medpace Second Quarter Earnings Conference Call. [Operator Ins ...